Literatur
-
1
Bailon P, Palleroni A, Schaffer C A. et al .
Rational design of a potent, long-lasting
form of interferon: a 40 kDa branched polyethylene glycol-conjugated
interferon alpha-2a for the treatment of hepatitis C.
Bioconjug
Chem.
2001;
12
195-202
-
2
EASL International Consensus
Conference on Hepatitis C .
Consensus Statement.
J
Hepatol.
1999;
1
3-11
-
3
Fried M, Shiffmann M, Reddy K. et al .
Pegylated
(40 kDa) interferon alpha 2a (PEAGSYS) in combination with ribavirin:
efficacy and safety results from a phase III, randomized, actively
controlled multicenter study.
Gastroenterology.
2001;
120
A55
-
4
Glue P, Fang J W, Rouzier-Panis R. et al. Hepatitis C
Intervention Therapy Group .
Pegylated interferon-alpha
2b: pharmacokinetics, pharmacodynamics, safety, and preliminary
efficacy data.
Clin Pharmacol Ther.
2000;
68
556-567
-
5
Harris J M, Martin N E, Modi M.
Pegylation:
a novel process for modifying pharmacokinetics.
Clin Pharmacokinet.
2001;
40
539-551
-
6
Heathcote E J, Shiffman M L, Cooksley W G. et al .
Peginterferon alpha-2a in patients with
chronic hepatitis C and cirrhosis.
N Engl J Med.
2000;
343
1673-1680
-
7
Jen J F, Glue P, Ezzet F. et
al .
Population pharmacokinetic analysis of pegylated
interferon alpha-2b and interferon alpha-2b in patients with chronic
hepatitis C.
Clin Pharmacol Ther.
2001;
69
407-421
-
8
Lindsay K L, Trepo C, Heintges T, Shiffman M L, Gordon C.
A
randomized, double-blind trial comparing pegylated interferon alpha-2b
to interferon alpha-2b as initial treatment for chronic hepatitis C.
Hepatology.
2001;
34
395-403
-
9
Manns M P, McHutchison J G, Gordon S C. et al .
Peginterferon alpha-2b plus ribavirin compared
with interferon alpha-2b plus ribavirin for initial treatment of
chronic hepatitis C: a randomised trial.
Lancet.
2001;
358
958-962
-
10
Martin P, Mitra S, Farrington K, Martin N E, Modi M W.
Pegylated (40
kDa) interferon alpha-2a (PEGASYS) is unaffected by renal impairment.
Hepatology.
2000;
32
A370
-
11
Modi M W, Fulton J S, Buckmann D K, Wright T L, Moore D J.
Clearance
of pegylated (40 kDa) interferon alpha-2a (PEGASYS) is primarily
hepatic.
Hepatology.
2000;
32
A371
-
12
Modi M W, Fried M, Reindollar R W. et al .
The pharmakokinetic behaviour of pegylated
(40 kDa) interferon alpha-2a (PEGASYS) in chronic hepatitis C patients
after multiple dosing.
Hepatology.
2000;
32
A394
-
13
Niederau C, Lange S, Heintges T. et al .
Prognosis of chronic hepatitis C: results
of a large, prospective cohort study.
Hepatology.
1998;
28
1687-1695
-
14
Poynard T, McHutchinson J, Goodman Z. et al .
Is an »A la carte« combination
interferon alpha2b plus ribavirin regimen possible for the first
line treatment in patients with chronic hepatitis C?.
Hepatology.
2000;
31
211-217
-
15
Reddy K R, Wright T L, Pockros P J. et al .
Efficacy and safety of pegylated (40-kd)
interferon alpha-2a compared with interferon alpha-2a in noncirrhotic
patients with chronic hepatitis C.
Hepatology.
2001;
33
433-438
-
16
Zeuzem S, Feinman S V, Rasenack J, Heathcote E J. et al .
Peginterferon
alpha-2a in patients with chronic hepatitis C.
New Engl
J Med.
2000;
343
1666-1671
-
17
Zeuzem S, Herrmann E, Lee J H. et al .
Viral kinetics in patients with chronic
hepatitis C treated with standard or peginterferon alpha2a.
Gastroenterology.
2001;
120
1438-1447
-
18
Algranti N E, Sy S, Modi M. et
al .
A branched methoxy 40 kDa polyethylene glycol (PEG)
moiety optimizes the pharmacokinetics of peginterferon alpha 2a
and may explain its enhanced efficacy in chronic hepatitis C (CHC).
Hepatology.
1999;
30
190A
-
19
Glue P, Fang J WS, Sabo R. et al .
PEG-interferon-α-2b:
pharmacokinetics, pharmacodynamics, safety and preliminary efficacy
data.
Hepatology.
1999;
30
189A
Korrespondenz
Prof. Dr. Claus Niederau
Kinik für Innere Medizin, St. Josef
Hospital Oberhausen, Akademisches Lehrkrankenhaus der Universität
Essen
Mülheimer Straße 83
46045 Oberhausen
Phone: 0208/837301
Fax: 0208/837309
Email: claus.niederau@st-josef.de
